With one in five Americans living with mental illness, the Kennedy Forum believed it was critical that mental health reform took prominence in policy discussions during the 2020 election season. The Kennedy Forum sought CURA’s support in building a movement that would bring mental health and addiction reform to the forefront of national policy talks.

New scientific advances and regulatory flexibility sparked a wave of innovation in rare kidney disease, which had seen no new treatments in 80 years. Travere Therapeutics engaged CURA for several projects over the last five years to educate public and private policymakers and influencers. Through stakeholder roundtables, consensus reports, Hill events and issue briefs, CURA has helped champion the New Era of Preventing End-Stage Kidney Disease Act.

Despite growing awareness of the opioid crisis, addiction and recovery remain highly stigmatized—

impacting those in recovery along with their support networks. Mobilize Recovery sought CURA’s support in launching a first-of-its-kind national service campaign that would break down stigma, build connections and showcase the power of the recovery community as changemakers through acts of volunteerism.

Nearly one in four patients admitted to U.S. hospitals experience preventable harm. The Leapfrog Group (LFG), a national nonprofit organization driving a public health and policy movement in patient safety, engaged CURA Strategies to become their agency of record with the ultimate goal of increasing the public’s awareness of patient safety and the importance of hospital transparency to improve outcomes.

Mamatoto Village, a D.C.-based maternal health nonprofit, needed help raising its national profile to match the impact of its community-based care model.

While the organization was deeply trusted locally, it was under-recognized at the national level. CURA was brought on to shape a media strategy that would elevate Mamatoto as a leading voice in Black maternal health and position it as a model for other birthing centers.

An estimated 35,000 patients in the United States are born with a single ventricle — one of the most complex heart defects. Currently, there are no FDA-approved therapies available for this patient population. Mezzion is conducting a Phase 3 clinical trial to evaluate whether its treatment can preserve and extend cardiac function. CURA has partnered with Mezzion to elevate their presence in the congenital heart disease community to strengthen their credibility and accelerate trial recruitment.

At the height of the opioid epidemic, medication-assisted treatment (MAT) was an undervalued tool, misunderstood by policymakers in Congress and at HHS. CURA Strategies designed and operationalized Advocates for Opioid Recovery (AOR) to help break down legislative, insurance, legal and regulatory barriers to evidence-based recovery from opioid use disorder.

Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on CAR T-cell therapy for autoimmune conditions, sought a partner to support their stakeholder engagement and clinical trial recruitment efforts. 

CURA partnered with Kyverna to engage leading patient influencers in the autoimmune space to increase awareness of CAR T-cell therapy and Kyverna’s work. This resulted in lasting partnerships and increased engagement among high-value patient communities.

As the largest private funder of polycystic kidney disease (PKD) research in the U.S., the PKD Foundation supports education, advocacy and awareness of PKD, a chronic, genetic condition that often leads to renal failure.

Over the last six years, CURA has worked with the PKD Foundation to implement a comprehensive advocacy strategy that connects and engages key stakeholders to promote a clear set of legislative priorities in Washington, D.C.

The American College of Cardiology (ACC) is one of the largest cardiovascular medical societies in the world with over 54,000 members.

ACC partnered with CURA to to raise its profile as the leading source for cutting-edge cardiovascular science while expanding its media footprint beyond traditional medical trade outlets.